Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

FEMY

Femasys Inc

Dec 13 • 04:00PM ET

1.19

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: IOVA AXSM KALA MANH TMDX VRCA HSDT LBRT HOOK ONVO

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.82	Insider Own	7.40%	Shs Outstand	22.23M	Perf Week	6.25%
Market Cap	27.25M	Forward P/E	-	EPS next Y	-0.49	Insider Trans	0.00%	Shs Float	21.20M	Perf Month	15.53%
Income	-18.10M	PEG	-	EPS next Q	-0.18	Inst Own	7.10%	Short Float	2.74%	Perf Quarter	6.25%
Sales	1.26M	P/S	21.63	EPS this Y	14.52%	Inst Trans	2.98%	Short Ratio	3.28	Perf Half Y	17.24%
Book/sh	0.27	P/B	4.43	EPS next Y	37.74%	ROA	-118.95%	Short Interest	0.58M	Perf Year	56.76%
Cash/sh	0.33	P/C	3.58	EPS next 5Y	-	ROE	-220.59%	52W Range	0.73 - 2.40	Perf YTD	22.05%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.85%	ROI	-142.75%	52W High	-50.42%	Beta	-2.88
Dividend TTM	-	Quick Ratio	3.26	Sales past 5Y	4.12%	Gross Margin	-5.24%	52W Low	62.13%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	3.94	EPS Y/Y TTM	15.92%	Oper. Margin	-1389.19%	RSI (14)	56.90	Volatility	7.66% 7.43%
Employees	32	Debt/Eq	1.21	Sales Y/Y TTM	15.33%	Profit Margin	-1436.04%	Recom	1.00	Target Price	8.25
Option/Short	No / Yes	LT Debt/Eq	1.12	EPS Q/Q	8.12%	Payout	-	Rel Volume	0.52	Prev Close	1.19
Sales Surprise	-18.06%	EPS Surprise	-20.00%	Sales Q/Q	127.09%	Earnings	Nov 12 BMO	Avg Volume	176.94K	Price	1.19
SMA20	10.05%	SMA50	3.89%	SMA200	-4.05%	Trades		Volume	92,847	Change	0.00%

Dec-03-24 09:00AM	Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed (GlobeNewswire)
Nov-26-24 08:30AM	Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed Infertility Treatment (GlobeNewswire)
Nov-12-24 09:45AM	Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -11.59%
08:30AM	Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update (GlobeNewswire)
Nov-07-24 08:30AM	Femasys to Exhibit at the Annual AAGL 2024 Global Conference (GlobeNewswire)
08:30AM	Loading…
Nov-01-24 08:30AM	Femasys Announces Issued U.S. Patent Covering FemBloc Device for Female Permanent Birth Control (GlobeNewswire) -5.26%
Oct-30-24 09:00AM	Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed (GlobeNewswire)
Oct-10-24 08:30AM	Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program (GlobeNewswire)
Oct-08-24 08:30AM	Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-02-24 08:30AM	Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed Infertility Treatments (GlobeNewswire)
Sep-18-24 08:30AM	Femasys Announces Infertility Clinic Customers from Coast to Coast (GlobeNewswire)
Sep-11-24 08:30AM	Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed for over $1.3M in Spanish Market (GlobeNewswire) +7.48%
Sep-09-24 11:53AM	FDA clears FemChec for fallopian tube occlusion testing (Medical Device Network)
08:30AM	Femasys Inc. Receives U.S. FDA Clearance to Market FemChec , an Innovative Diagnostic Solution for Fallopian Tube Check (GlobeNewswire)
Sep-05-24 08:30AM	Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting (GlobeNewswire)
08:30AM	Loading…
Sep-03-24 08:30AM	Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.84%
Aug-30-24 06:32AM	Femasys secures CE mark certification for FemVue MINI solution (Medical Device Network)
Aug-29-24 08:30AM	Femasys Announces CE Mark and Canadian Approval for FemVue MINI, a Fallopian Tube Assessment Solution (GlobeNewswire) +10.48%
Aug-27-24 08:30AM	Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters (GlobeNewswire)
Aug-08-24 09:45AM	Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -18.09%
08:30AM	Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update (GlobeNewswire)
Jun-27-24 08:30AM	Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam (GlobeNewswire) +10.58%
Jun-21-24 04:32AM	Femasys gains CE Mark approval for womens health products (Medical Device Network) -9.45%
Jun-20-24 08:30AM	Femasys Receives CE Mark Approval for Four of its Women's Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe (GlobeNewswire) +32.98%
May-17-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative (GlobeNewswire)
May-16-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council (GlobeNewswire)
May-09-24 01:53PM	FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -8.63%
09:40AM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:30AM	Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update (GlobeNewswire)
May-07-24 08:30AM	Femasys Expands Commercial Management Team with Addition of Experienced New Hires (GlobeNewswire) +5.19%
10:01AM	Loading…
May-02-24 10:01AM	Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-18-24 08:30AM	Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare Initiatives (GlobeNewswire)
Mar-28-24 10:53PM	FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) +5.44% +10.97%
04:05PM	Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update (GlobeNewswire)
Mar-21-24 09:00AM	Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape (GlobeNewswire)
Mar-20-24 08:15AM	Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility (GlobeNewswire) -10.00%
Mar-13-24 09:00AM	Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024 (GlobeNewswire) -5.24%
Mar-06-24 09:00AM	Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution (GlobeNewswire) -11.27%
Feb-28-24 09:00AM	Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF (GlobeNewswire) +9.26%
Feb-06-24 08:30AM	Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer (GlobeNewswire) +13.27%
Jan-26-24 08:00AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women (GlobeNewswire)
Jan-23-24 08:30AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology (GlobeNewswire)
Dec-15-23 08:30AM	Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine (GlobeNewswire)
Nov-30-23 08:30AM	Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 05:27PM	30 Countries with the Lowest Median Age in the World (Insider Monkey)
08:30AM	Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch (GlobeNewswire)
Nov-23-23 03:38PM	20 Countries with the Highest Teenage Pregnancy Rates (Insider Monkey)
Nov-15-23 08:30AM	PharmaCyte Biotech Acquires $5 Million Stake in Emerging Womens Health Innovator Femasys, Inc. (Business Wire) +8.60%
07:30AM	Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech (GlobeNewswire)
Nov-14-23 07:00AM	Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update (GlobeNewswire) -10.58%
Oct-30-23 02:02PM	12 Best Stocks For Day Trading (Insider Monkey) +20.87%
Oct-26-23 08:30AM	Femasys Inc. EU MDR Final Audit Successfully Completed (GlobeNewswire)
Oct-25-23 08:00AM	Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women's Health at the American Association of Gynecologic Laparoscopic Surgeons (GlobeNewswire)
Oct-24-23 04:13AM	Femasys (FEMY) to Report Q3 Earnings: What's in the Cards? (Zacks) +5.98%
Oct-11-23 07:00AM	Femasys Inc. Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -6.25%
Oct-04-23 08:30AM	Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine (GlobeNewswire) -8.03%
Oct-03-23 08:30AM	Femasys Inc. MDSAP Surveillance Audit Successfully Completed (GlobeNewswire) -35.99%
Oct-02-23 07:08PM	3 Micro-Cap Stocks Set to Explode Higher (InvestorPlace) +30.54%
Sep-27-23 08:00AM	Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate (GlobeNewswire) -25.00%
Sep-25-23 05:25PM	Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution (GlobeNewswire) +6.97% +346.32%
Sep-20-23 08:30AM	Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control (GlobeNewswire)
Sep-06-23 08:30AM	Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 08:30AM	Femasys Inc. Obtains Medical Device Establishment License from Health Canada (GlobeNewswire)
Aug-10-23 08:00AM	Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update (GlobeNewswire) -6.50%
Aug-03-23 08:45AM	Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc (GlobeNewswire)
Jul-27-23 08:45AM	Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control (GlobeNewswire) +130.77%
Jul-03-23 09:55AM	Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' Now (Zacks)
Jun-26-23 08:00AM	Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women (GlobeNewswire) +6.25%
Jun-15-23 08:00AM	Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences (GlobeNewswire) +10.87%
Jun-14-23 08:00AM	Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023 (GlobeNewswire) -5.97%
Jun-08-23 08:30AM	Femasys FemCath Intrauterine Catheter Receives Product Approval in Canada (GlobeNewswire) -9.99%
May-11-23 04:05PM	Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023 (GlobeNewswire) -13.15%
08:30AM	Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting (GlobeNewswire)
May-03-23 08:30AM	Femasys FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada (GlobeNewswire)
May-01-23 04:05PM	Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology (GlobeNewswire) +6.09%
Apr-19-23 08:00AM	Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.61%
Apr-18-23 08:00AM	Femasys FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada (GlobeNewswire) +16.67%
Mar-30-23 08:00AM	Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update (GlobeNewswire)
Mar-09-23 08:00AM	Femasys Inc. to Participate in The Post-Roe Fertility Journey Panel Discussion at SXSW 2023 (GlobeNewswire) -8.80%
Dec-19-22 09:00AM	Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device (GlobeNewswire)
Dec-12-22 08:30AM	Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons (GlobeNewswire)
Nov-29-22 07:00AM	Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design (GlobeNewswire) -8.13%
Nov-21-22 08:30AM	Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-12-22 08:17AM	Femasys Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-10-22 09:55AM	Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +5.98%
08:44AM	Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update (GlobeNewswire)
Oct-20-22 08:00AM	Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement (GlobeNewswire)
Oct-14-22 04:05PM	Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress (GlobeNewswire)
Oct-12-22 08:00AM	Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs (GlobeNewswire) -16.15%
Oct-06-22 08:01AM	Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control (GlobeNewswire)
Sep-29-22 08:00AM	Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team (GlobeNewswire)
Sep-01-22 04:05PM	Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-10-22 05:45PM	Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.10%
04:05PM	Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update (GlobeNewswire)
Aug-03-22 08:00AM	Femasys To Participate in Upcoming BTIG Biotechnology Conference (GlobeNewswire) +8.81%
Jul-20-22 07:00AM	Femasys To Host Key Opinion Leader Event on FemBloc, a First-of-its-Kind Medical Solution for Permanent Birth Control and an Important Option for Women Post Overturn of Roe v. Wade (GlobeNewswire)
Jul-11-22 08:30AM	Femasys to Participate in the Womens Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET (GlobeNewswire) -6.30%
Jul-06-22 08:00AM	Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board (GlobeNewswire) +5.76%
Jun-28-22 05:31PM	2 Contraceptive Stocks That Could Benefit From Roe v. Wade Reversal (TipRanks) +7.39%
Jun-15-22 08:00AM	Femasys Inc. to Present at the LSX World Congress USA 2022 (GlobeNewswire) -7.14%

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FEMY

Femasys Inc

Upgrade your FINVIZ experience